Biotech | March 03, 2022
Medix Biochemica announces expansion of its porfolio
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
The product will be manufactured at Lupin’s facility in Pithampur, India
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
This has further strengthened its manufacturing presence in the United States of America
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
110 BDS graduates admitted in week one of the launch
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
Subscribe To Our Newsletter & Stay Updated
